ATE175211T1 - Neues, biologisch aktives, vom frosch stammendes peptid (frosch-cnp) - Google Patents

Neues, biologisch aktives, vom frosch stammendes peptid (frosch-cnp)

Info

Publication number
ATE175211T1
ATE175211T1 AT91115079T AT91115079T ATE175211T1 AT E175211 T1 ATE175211 T1 AT E175211T1 AT 91115079 T AT91115079 T AT 91115079T AT 91115079 T AT91115079 T AT 91115079T AT E175211 T1 ATE175211 T1 AT E175211T1
Authority
AT
Austria
Prior art keywords
frog
cnp
biologically active
derived peptide
new biologically
Prior art date
Application number
AT91115079T
Other languages
English (en)
Inventor
Hisayuki Matsuo
Kenji Kangawa
Naoto Minamino
Original Assignee
Suntory Ltd
Hisayuki Matsuo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd, Hisayuki Matsuo filed Critical Suntory Ltd
Application granted granted Critical
Publication of ATE175211T1 publication Critical patent/ATE175211T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
AT91115079T 1990-09-07 1991-09-06 Neues, biologisch aktives, vom frosch stammendes peptid (frosch-cnp) ATE175211T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2238294A JP2977159B2 (ja) 1990-09-07 1990-09-07 カエル由来新規生理活性ペプチド（カエルｃｎｐ）

Publications (1)

Publication Number Publication Date
ATE175211T1 true ATE175211T1 (de) 1999-01-15

Family

ID=17028056

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91115079T ATE175211T1 (de) 1990-09-07 1991-09-06 Neues, biologisch aktives, vom frosch stammendes peptid (frosch-cnp)

Country Status (8)

Country Link
US (1) US5336759A (de)
EP (1) EP0475290B1 (de)
JP (1) JP2977159B2 (de)
AT (1) ATE175211T1 (de)
DE (1) DE69130695T2 (de)
DK (1) DK0475290T3 (de)
ES (1) ES2127189T3 (de)
GR (1) GR3029632T3 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
ES2465141T3 (es) 2004-03-31 2014-06-05 Kazuwa Nakao Remedio o medicamento preventivo para la artritis
WO2005094890A1 (ja) 2004-03-31 2005-10-13 Kazuwa Nakao 身長増加用組成物
CA2559228C (en) 2004-04-21 2016-06-21 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone
JP2010539002A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト ウロジラチンの治療剤としての使用
WO2012088608A1 (en) 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
MX389350B (es) 2014-12-05 2025-03-19 Alexion Pharma Inc Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones.
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
CN108350440A (zh) 2015-08-17 2018-07-31 阿雷克森制药公司 碱性磷酸酯的制造
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
JP7613826B2 (ja) 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (de) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa zur behandlung von tracheobronchomalazie
EP3600383A4 (de) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von hypophosphatasie (hpp) bei erwachsenen und jugendlichen
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
AU2021337652B2 (en) 2020-09-04 2025-01-30 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2544929B2 (ja) * 1987-06-17 1996-10-16 第一化学薬品 株式会社 新規生理活性ペプチド
US5114923A (en) * 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
JPH04120095A (ja) 1992-04-21
DE69130695D1 (de) 1999-02-11
ES2127189T3 (es) 1999-04-16
US5336759A (en) 1994-08-09
EP0475290B1 (de) 1998-12-30
GR3029632T3 (en) 1999-06-30
DE69130695T2 (de) 1999-06-10
DK0475290T3 (da) 1999-08-30
JP2977159B2 (ja) 1999-11-10
EP0475290A1 (de) 1992-03-18

Similar Documents

Publication Publication Date Title
ATE175211T1 (de) Neues, biologisch aktives, vom frosch stammendes peptid (frosch-cnp)
DE69130696D1 (de) Ein neues, biologisch aktives vom Huhn stammendes Peptid (Huhn-CNP)
ATE145914T1 (de) Anticonvulsive fructopyranose zyklische sulfate und sulfite
IT8921742A0 (it) Procedimento per la purificazione delle acque reflue prodotte dagli impianti di produzione dell'urea.
DK0696937T3 (da) Fremgangsmåde til behandling af spontant forbrændelige katalysatorer
FI885504A0 (fi) Vaskulaera antikoagulerande proteiner, dessa koderande dna, deras framstaellningsfoerfarande och deras anvaendning.
ATE152734T1 (de) Bpc-peptide, deren herstellung und verwendung
PT641215E (pt) Analogos de trombomodulina resistentes a proteases
DE69010442D1 (de) Reinigung von 1,1-Dichlor-1-fluorethan.
DE69534470D1 (de) Lgmd- gen kodierend für einer calcium abhängigen protease
DE3689008D1 (de) Verfahren zur Herstellung und Reinigung von alpha-Interferon.
DE69116803D1 (de) Peroxidase-Gen von mikrobischem Ursprung
DE59602774D1 (de) Verfahren zur Herstellung von 3.3.5-Trimethylcyclohexanon
ATE209683T1 (de) Planze resistent gegen mindestens zwei viren und dessen preparation
DE59008482D1 (de) Verfahren zur Herstellung von 2,4,5-Triamino-6-hydroxypyrimidin durch katalytische Hydrierung von 2,4-Diamino-6-hydroxy-5-nitrosopyrimidin.
ES2039312T1 (es) Peptido bacteriocinico.
ATE92077T1 (de) Enzymhemmer und methode zu dessen herstellung.
DE69314086D1 (de) Verfahren zur Reinigung von 4,4'-Diaminodiphenylmethan
FI873353A7 (fi) Jätevesien biologinen käsittelytapa kaskadimaisesti toimivan uppobiosuodatuslaitoksen avulla.
IT8941638A0 (it) Procedimento ed impianto per il recupero di bitartrato di potassio dalle acque reflue di rigenerazione di impianti di deionizzazione del mosto d'uva.
IT8423089A1 (it) Solubilizzazione di ossigeno mediante adsorbimento dell'ossigeno nei fanghi biologici degli impianti di depurazione a fanghi attivi
IT9047825A0 (it) Impianto prefabbricato per il procedimento di trattamento di depurazione di liquami fognari cittadini, o scarichi industriali.
SE8403252L (sv) Forfarande vid forbrenning, jemte brensle
DE3765250D1 (de) Verwendung von 24,25-dihydroxycholecalciferol zur behandlung von harnsteinen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee